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Abstract
This is a case of 32 years old nulliparous female who was diagnosed in November
2004 as a case of carcinoma of the right breast , luminal A , (Estrogen Receptor
positive Progesterone receptor negative, Her 2 negative, Ki67 10 %), poorly
differentiated invasive ductal cancer, TNM stage,T2 N0 MO. She had a wide local
excision and axillary clearance. As she is a case of low risk early stage luminal
A breast cancer; she was not given chemotherapy, instead she had a course of
external irradiation and was put on Tamoxifen (Astra Zeneca, 20 mg daily), and was
advised not to get pregnant during this treatment, but she got pregnant and delivered
normally a healthy infant, although Tamoxifen is potentially teratogenic.
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هذه هى حالة دراسة المراة تبلغ ٣٢ عاما لم تحمل من قبل تم تشخيصها يف نوفمبر ٢٠٠٤ 
االستروجين، سلبية مستقبالت  (إيجابية مستقبالت   ،A اللمعية  األيمن،  الثدي  بسرطان 
التمييز،تمرحل القنوات الغازى فقير  البروجسترون ، سلبية  Her٢ ، Ki٦٧  ١٠٪) سرطان 
MNT ، T٢ ٠M  N٠. اجرى لها استئصال موضعى واسع وتنظيف لإلبطين. وبما انها حالة 
منخفضة المخاطر يف وقت مبكر مرحلة اللمعية من سرطان الثدي. لم تحصل على العالج 
(أسترا  تاموكسيفين  على  ووضعت  الخارجي  التشعيع  من  دورة  اعطيت  بل  الكيميايئ، 
زينيكا، ٢٠ ملغ يوميا)، ونصحت بعدم الحمل أثناء هذا العالج، لكنها حصلت على الحمل 
يكون  أن  يحتمل  التاموكسيفين  أن  من  الرغم  على  صحيحا،  طفل  طبيعيا  وووضعت 
مسخيا.
1. Introduction
Breast cancer is the commonest cancer among females worldwide. In Sudan it’s the
leading cancer in females. It forms (30–34%) of all female cancers, 40% are below the
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age of 45years, i.e. within the reproductive age, this reflects our population pyramid [1].
Carcinoma of the breast is the most common malignancy occurring during pregnancy
[2]. Tamoxifen is a non-steroidal drug which has estrogenic and an anti-estrogenic
effect. It stimulates ovulation and has a teratogenic effectwhen used during pregnancy
that has been established in animals and humans [3].
2. Case Report
A thirty two years old married patient with good performance status, and no co mor-
bidities presented to us in November 2004 with a right breast central 3x3cm ,firm
lump, and no other abnormality on clinical examination. She has no family history of
breast cancer, her CBC, UE and LFT and CT Chest and CT abdomen and pelvis were
normal. She had a true- cut needle biopsy, positive for a poorly differentiated invasive
ductal carcinoma, grade three. Breast conservative surgery and a xillary clearance
were performed, and the histopathology report showed (2.5 x 2 cm) mass, with 12
out of 12 reactive lymph nodes, grade III invasive ductal cancer, negative margins,
more than 1.5 cm in all directions, with negative skin, nipple, and no lymph vascular
invasion. ER positive (6/8), PR positive (5/8), Her2 negative, Ki 67% = 10 % as she has
a Luminal A, low risk stage (T2 N0 M0) breast cancer. She was given a course of external
irradiation (40 Gy/15 fractions) by Co60 excluding the axilla, and (Tamoxifen 10mg twice
per day, Astra Zeneca). She and her husband were counseled, and she was advised not
to get pregnant during this treatment and to use an intrauterine contraceptive device
(IUCD). The risks of getting pregnant during this treatment were well explained. She
was advised to come for regular follow up, and in case she gets pregnant to stop
Tamoxifen and come immediately for follow up.
She remained well, until September 2011, when she was seen at an antenatal clinic,
where a four months pregnancy was confirmed and was therefore referred to us.
Abdominal ultrasound showed 17weeks gestation with no abnormality, (EDD = 10th Feb
2012), and no evidence of metastases. Clinically there was no evidence of local recur-
rence or metastases. Her laboratory investigations were normal. After counseling the
couple, they were very keen to keep the pregnancy and accepted the consequences,
as she is a nulliparous and they were married for 4 years. So the pregnancy was main-
tained, and she was followed with regular ultrasound of the abdomen. Amniocentesis
testing was not a available, she delivered normally a healthy infant on the 15th Feb
2012.
She was then followed regularly; she remained well with no evidence of disease
when she was last seen at the follow up clinic in March 2017.
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3. Discussion
Breast cancer is the commonest cancer in Sudanese women [1]. During pregnancy
Tamoxifen and its metabolites affects the rapidly growing fetal tissue. It leads to birth
defects in 20% of exposures [2–9]. Astra Zeneca data base records of patients exposed
to Tamoxifen during pregnancy, showed 16 live births with congenital abnormalities
and 122 live births without malformations. In addition there were 12 spontaneous abor-
tions, 17 terminations of pregnancy without fetal defects, six terminations of preg-
nancy with fetal defects, two still births without malformations, two still births with
malformation and another 57 unknown outcomes [10].
Tamoxifen induced abnormalities include Goldenhar’s syndrome; ambiguous geni-
talia, vaginal bleeding and abortions, yet several reports described exposure to Tamox-
ifen with healthy neonates [5]. Clark et.al studied 85 healthy women with high risk of
developing breast cancer who were given Tamoxifen prophylactially. They became
pregnant while on Tamoxifen, with no fetal abnormalities observed after deliveries
[11]. A case reported by Tewari et.al described a case of an infant borne with ambigu-
ous genitalia, and three other case reports described four live births with congenital
anomalies, no specific abnormality is identified to be associated with exposure to
Tamoxifen during pregnancy [4]. The relatively high frequency of congenital abnormal-
ities means that reliable birth control during Tamoxifen treatment is essential during
its use and a washout period of two months should be observed based on the known
half-life of Tamoxifen. So, there is a general agreement to postpone Tamoxifen treat-
ment until after delivery [10]. There are no prospective studies assessing the effect of
termination of pregnancy on survival.
Our patient got pregnant while on Tamoxifen, in spite of the fact that she and
her husband were counseled, the risks were explained, and was advised not to get
pregnant while on Tamoxifen and to have an intrauterine contraceptive device, but
she didn’t use any form of contraception as she was very keen to get pregnant due to
the social pressures from the husband and the family and the fear that her husband
may divorce her or remarry. But fortunately she delivered a normal infant, similar
cases were reported by Isaacs et al. [7], Oksuzogolo et al. [9], and Emra Koca et al.
[12].
4. Conclusion
Using Tamoxifen during pregnancy is contraindicated because it causes birth defects in
20% of the cases, so good counseling of Breast Cancer premenopausal women treated
with Tamoxifen is important. They should be advised not to get pregnant and to stop
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tamoxifen immediately if they get pregnant. We reported a case where tamoxifen was
used during pregnancy and luckily there were no birth defects.
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